FDA issued final guidance on November 10 on validating in vitro diagnostics for emerging pathogens during a section 564 declared emergency, nearly two years after the January 2025 draft. It covers molecular and antigen tests submitted in a pre-EUA or EUA request, or offered under an enforcement discretion policy. Serology and antibody tests are out of scope.

The numbers are the useful part. For a viral nucleic acid test on established, highly sensitive technology, 30 positive and 30 negative specimens from the intended use population are typically adequate. Limit of detection should be confirmed with at least 20 replicates, and simulated matrices are not acceptable. Molecular inclusivity means 100 percent nucleotide identity, assessed in silico, backed by wet testing of circulating variants, and revisited monthly. A sensitivity drop of more than threefold for a variant calls for a risk analysis.

For a CLIA waived point-of-care test, FDA wants one or two US sites, four to six untrained operators, and 10 contrived near-LoD samples plus 10 negatives per site, at 95 percent agreement or better. Home use instructions should run one to two pages at no higher than a seventh grade reading level. FDA also renamed the draft's predetermined change control plans to change protocols, to keep them distinct from the marketing submission version.

The cautionary example in the guidance is worth reading before anyone builds a 12-sample validation deck. One COVID-19 request showed perfect performance on 12 positives, then fell to 71 percent positive percent agreement after 12 more, and was withdrawn. Comments stay open under docket FDA-2024-D-2707.